At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 14 enrolled
Drug / intervention
Pantoprazole +1 moredrug
Likely dose
Pantoprazole 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Pantoprazole on Insulin Secretion in Patients With Type 2 Diabetes
Coordinación de Investigación en Salud, Mexico·interventional·Posted Mar 1, 2012·Updated Feb 21, 2014
In Brief
A Phase 3 clinical trial evaluating Pantoprazole and placebo for Type 2 Diabetes. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate the effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedMar 2012
Primary CompletionMar 2013
Study CompletionMay 2013
TodayJul 2026
First PostedMar 1, 2012
Enrollment StartJan 1, 2012
Primary CompletionMar 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.3 years ago
Interventions
Pantoprazoledrug
The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
placebodrug
Placebo 40 mg dose.